Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
861-880 of 3,900 trials

Tumor Treatment: Botensilimab and Balstilimab Study

We are studying a new combination of immune therapies for patients with specific tumor types to see if it can reduce tumor size before surgery. This trial aims to improve treatment effectiveness and safety.

dMMR Tumors≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Early Breast Cancer: Elacestrant and Ribociclib Study

We are testing a new treatment combination of elacestrant and ribociclib for patients with hormone-sensitive early breast cancer. The goal is to see if this combination works better than standard therapies before surgery.

Hormone Receptor Positive HER2 Negative Breast Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Hereditary Angioedema: PHA-022121 Treatment Study

We are testing the safety of a new oral medication for treating acute angioedema attacks in patients with hereditary angioedema. The study will also evaluate how well it relieves symptoms during these attacks.

Hereditary AngioedemaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Lung Cancer Treatment: Livmoniplimab and Budigalimab

We are studying a new combination of drugs for adults with untreated metastatic non-squamous non-small cell lung cancer. The goal is to see if this combination works better than a standard treatment with pembrolizumab and chemotherapy.

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Mild Age-Related Hearing Loss: DX243 Treatment

We are testing a new treatment for people with mild age-related hearing loss to see if it is safe and effective. The study starts with healthy volunteers before moving to patients.

Age-Related Hearing Loss>2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineOtolaryngology

Immune Thrombocytopenia: New Combination Therapy

We are studying a new treatment combining four medications for patients with immune thrombocytopenia. The trial will evaluate its effectiveness, safety, and impact on quality of life.

Immune ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

B-cell Non-Hodgkin Lymphoma: Surovatamig Treatment Study

We are studying how well surovatamig works and its safety for adults with certain types of blood cancers. This trial aims to learn more about its effects on lymphoma and patient experiences.

Relapsed or Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Diabetic Retinopathy: COLIRIOBCN070660 Eye Drops

We are studying a new eye drop treatment for people with moderately severe to severe diabetic retinopathy. The goal is to see if it can reduce eye damage and improve vision.

Diabetic Retinopathy1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesEndocrinologyOphthalmology

Cardiovascular Disease: New Care Strategies for Type 1 Diabetes

We are testing a new care approach to reduce cardiovascular disease risk in people with type 1 diabetes. This study also evaluates the safety of a medication called finerenone in this high-risk group.

Type 1 Diabetes>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Severe Hemophilia A: Efanesoctocog Alfa Study

We are comparing a new treatment, efanesoctocog alfa, with other existing therapies for severe hemophilia A. This study aims to understand how well it works in managing the condition.

Haemophilia A1-2 yearsSafety phase (I)Hematology

Nonsegmental Vitiligo: Ritlecitinib Study

We are investigating the safety and effectiveness of ritlecitinib in adults and adolescents with nonsegmental vitiligo. This study looks at how well the medication works over time for those who have already been treated.

Non-Segmental Vitiligo1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Acute Myeloid Leukemia: MB-dNPM-1-TCR.1 Treatment

We are studying a new therapy for patients with relapsed or refractory acute myeloid leukemia. The goal is to understand its safety and how well it works compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Baricitinib for Uveitis in Children with Juvenile Idiopathic Arthritis

We are studying whether the oral medication baricitinib is safe and effective for children aged 2 to under 18 with active uveitis linked to juvenile idiopathic arthritis. This research aims to improve treatment options for these young patients.

UveitisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Hidradenitis Suppurativa: New Antibiotic Treatment Study

We are evaluating a new antibiotic regimen for people with Hurley stage 2 Hidradenitis Suppurativa to see if it works better than standard treatment. The study will also look at pain relief and quality of life improvements.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatologyInfectious Diseases

Lupus Nephritis: Obinutuzumab for Adolescents

We are studying the effects of obinutuzumab in adolescents with active lupus nephritis to see if it is more effective than a placebo. The trial also includes younger children to evaluate safety and how the drug works in them.

Lupus Nephritis>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteNephrologyPediatricsRheumatology

Acute Myeloid Leukemia: Emavusertib Treatment Study

We are testing a new drug, Emavusertib, for patients with acute myeloid leukemia who still have traces of the disease while on other treatments. The goal is to see if it improves their condition.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Oncology

Epcoritamab for Relapsed Primary CNS Lymphoma

We are studying the effects of epcoritamab in patients with relapsed primary diffuse large B-cell lymphoma of the CNS who have been treated with lenalidomide and rituximab. The trial aims to evaluate its effectiveness, safety, and impact on quality of life.

Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the CNS>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyNeurologyOncology

Asthma Management: BIRDIE Trial

We are exploring if we can safely extend the dosing schedule of two asthma medications for patients with severe eosinophilic and T2-high asthma. This study looks at whether this approach maintains asthma control.

Severe AsthmaConfirmation phase (III)No PlaceboStandard MedicinesAllergologyPulmonology

B-Cell Acute Lymphoblastic Leukemia: AZD0486 Study

We are investigating whether AZD0486 is safe and effective for adolescents and adults with relapsed or refractory B-cell acute lymphoblastic leukemia. This trial aims to understand how well it works compared to existing treatments.

B-Cell Acute Lymphoblastic LeukaemiaSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Juvenile Idiopathic Arthritis: Filgotinib Study

We are studying how the medication filgotinib works in children and teens with juvenile idiopathic arthritis. The trial will also evaluate its safety and how well young patients accept the medication.

Juvenile Idiopathic Arthritis≤3 monthsSafety phase (I)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPediatricsRheumatology